Overview

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, 2-period parallel study in healthy subjects to assess immunogenicity and safety of two sequential 6 mg subcutaneous (SC) injections of CHS-1701 compared with two sequential 6 mg SC injections of Neulasta®.
Phase:
Phase 1
Details
Lead Sponsor:
Coherus Biosciences, Inc.